Welcome to our dedicated page for United-Guardian news (Ticker: UG), a resource for investors and traders seeking the latest updates and insights on United-Guardian stock.
Founded in 1942, United-Guardian, Inc. (symbol: UG) stands as a reputable entity in the domains of cosmetic ingredients, pharmaceuticals, medical products, and specialty industrial products. With a rich history spanning over seven decades, the company has established a robust presence through a global network of marketing partners, catering to most of the leading names in the global cosmetic industry.
United-Guardian's flagship product line includes an extensive array of water-based moisturizing and lubricating gels, which serve dual purposes in both cosmetic and medical applications. These products underscore the company's commitment to innovation and efficacy, ensuring high standards of quality and utility.
The product portfolio features renowned names such as Klensoft, Deselex, Renacidin, and Lubrajel Fluid. Klensoft and Deselex are pivotal in the cosmetic segment, enhancing product formulations with their unique properties. Renacidin, a key pharmaceutical product, and Lubrajel Fluid, known for its superior lubricating properties, demonstrate the company's versatile research and development capabilities.
United-Guardian markets its pharmaceutical products through full-line drug wholesalers across the United States, ensuring widespread availability. The medical and specialty industrial products are distributed directly to end-users or through contract manufacturers, highlighting a strategic approach to reach diverse markets.
With a focus on four distinct product categories - cosmetic ingredients, pharmaceuticals, medical lubricants, and sexual wellness - the company continually drives research and development to stay ahead in these competitive fields. The majority of the revenue is generated from sales within the U.S., reflecting a strong domestic market presence.
For more detailed financial information and the latest updates, visit the company’s official website at www.u-g.com.
United-Guardian, Inc. (NASDAQ:UG) has initiated a formal review process to explore strategic alternatives aimed at maximizing shareholder value. This review may include joint ventures, partnerships, or even a sale of the Company. President Ken Globus emphasized the need to position the Company for growth post-COVID-19, leveraging its established product portfolio and market relationships. Capstone Partners is assisting with financial advice, while Brownstein Hyatt Farber Schreck is providing legal counsel. No timelines for the review or specific outcomes were disclosed.
United-Guardian (NASDAQ:UG) declared a cash dividend of $0.65 per share, to be paid on December 7, 2021, for stockholders on record by November 29, 2021. This represents a 35% increase from the previous dividend of $0.48 this year and an 81% increase from $0.36 in December 2020. Ken Globus, President, noted the company's recovery from the pandemic has allowed them to enhance their financial position and provide a record total dividend of $1.13 for the year. The Board remains confident in overcoming potential supply chain issues moving into 2022.
United-Guardian (NASDAQ:UG) reported a 42% rise in net income for Q3 2021, reaching $1,016,506 ($0.22 per share), compared to $717,532 ($0.16) in Q3 2020. Net sales surged by 36% to $3,179,746, up from $2,336,360. For the first nine months of 2021, net income increased by 31% to $3,542,232 ($0.77 per share), with sales climbing 19% to $10,268,592. Cosmetic ingredient sales multiplied by 187%, boosted by a 300% increase from a partner in Asia. Despite ongoing supply chain challenges, the company anticipates continued growth into 2022.
United-Guardian, Inc. (NASDAQ:UG) reported a 24% increase in Q2 sales, reaching $3,657,978 compared to $2,954,644 in 2020. Net income rose from $1,186,611 ($0.26/share) to $1,344,524 ($0.29/share). For the first half of 2021, sales increased by 13% to $7,088,846, with net income rising from $1,976,918 ($0.43/share) to $2,525,726 ($0.55/share). A significant 68% growth in cosmetic ingredient sales was noted, although future projections remain uncertain due to the pandemic.
United-Guardian, Inc. (NASDAQ:UG) has announced a cash dividend of $0.48 per share, set to be paid on June 7, 2021, to all shareholders recorded by May 31, 2021. This marks the 26th consecutive year of dividends. The decision, made during the Board of Directors meeting on May 18, 2021, reflects strong first-quarter earnings and a positive outlook for the second quarter, with a 33% increase from the prior mid-year dividend. President Ken Globus expressed confidence in the company’s financial health and anticipated market recovery.
United-Guardian, Inc. (NASDAQ: UG) reported a 49% increase in net income for Q1 2021, rising to $1,181,202 ($0.26 per share) from $790,307 ($0.17 per share) in Q1 2020. Net sales also increased by 3% to $3,430,868. The growth was driven by higher sales of cosmetic ingredients, pharmaceutical products, and medical lubricants. The company noted an improvement in distributor inventory levels compared to the previous year, which had been impacted by the pandemic.
United-Guardian, Inc. (NASDAQ:UG) reported a profitable 2020 despite pandemic challenges, with sales at $10.99 million, down from $13.60 million in 2019. Net income was $3.30 million ($0.72 per share) compared to $4.76 million ($1.04 per share) in the prior year. The pandemic notably affected cosmetic ingredient sales in China, though early 2021 signals show positive trends. Pharmaceutical sales remained strong, and the company is optimistic about future recovery and revenue growth from new products.
United-Guardian (NASDAQ:UG) declared a cash dividend of $0.36 per share, to be paid on December 8, 2020, to stockholders recorded by December 1, 2020. Despite pandemic-related challenges, the company's strong balance sheet and profitable year prompted the board's decision, though they opted to reduce the dividend due to negative impacts on sales and earnings in the second half. The company remains optimistic about strong pharmaceutical sales and potential recovery in cosmetic ingredients as global conditions improve.
United-Guardian, Inc. (NASDAQ:UG) reported a net income of $717,532 ($0.16 per share) on sales of $2,336,360 for Q3 2020, a decline from $1,069,871 ($0.23 per share) on $3,317,370 in Q3 2019. Year-to-date, net income stands at $2,694,450 ($0.59 per share) with sales of $8,613,918, compared to $3,371,375 ($0.73 per share) on $9,777,086 in the same period last year. The decline is attributed to the pandemic's impact on consumer demand, particularly in personal care products, while pharmaceutical product demand increased by 9% and 15% for the quarter and year-to-date, respectively.
United-Guardian (NASDAQ:UG) reported a 10% increase in net income for Q2 2020, reaching $1,186,611 compared to $1,078,810 in Q2 2019, despite a 10% drop in sales from $3,279,399 to $2,954,644. Year-to-date sales also declined slightly to $6,277,558 from $6,459,716 in 2019, with net income decreasing to $1,976,918 ($0.43/share) from $2,301,504 ($0.50/share). The company expects continued strength in pharmaceutical and medical product sales, although cosmetic ingredient sales may decline due to the pandemic.
FAQ
What is the current stock price of United-Guardian (UG)?
What is the market cap of United-Guardian (UG)?
What does United-Guardian, Inc. specialize in?
When was United-Guardian, Inc. founded?
What are some key products of United-Guardian, Inc.?
How are United-Guardian's pharmaceutical products distributed?
What is the significance of water-based gels in United-Guardian's product line?
Which markets does United-Guardian primarily serve?
How does United-Guardian distribute its medical and specialty industrial products?
Where can I find more financial information about United-Guardian, Inc.?
What are the main product categories of United-Guardian?
Does United-Guardian conduct research and development?
